Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
PLoS One ; 16(11): e0259823, 2021.
Article in English | MEDLINE | ID: mdl-34748615

ABSTRACT

BACKGROUND: Pediatric SARS-CoV-2 data remain limited and seropositivity rates in children were reported as <1% early in the pandemic. Seroepidemiologic evaluation of SARS-CoV-2 in children in a major metropolitan region of the US was performed. METHODS: Children and adolescents ≤19 years were enrolled in a cross-sectional, observational study of SARS-CoV-2 seroprevalence from July-October 2020 in Northern Virginia, US. Demographic, health, and COVID-19 exposure information was collected, and blood analyzed for SARS-CoV-2 spike protein total antibody. Risk factors associated with SARS-CoV-2 seropositivity were analyzed. Orthogonal antibody testing was performed, and samples were evaluated for responses to different antigens. RESULTS: In 1038 children, the anti-SARS-CoV-2 total antibody positivity rate was 8.5%. After multivariate logistic regression, significant risk factors included Hispanic ethnicity, public or absent insurance, a history of COVID-19 symptoms, exposure to person with COVID-19, a household member positive for SARS-CoV-2 and multi-family or apartment dwelling without a private entrance. 66% of seropositive children had no symptoms of COVID-19. Secondary analysis included orthogonal antibody testing with assays for 1) a receptor binding domain specific antigen and 2) a nucleocapsid specific antigen had concordance rates of 80.5% and 79.3% respectively. CONCLUSIONS: A much higher burden of SARS-CoV-2 infection, as determined by seropositivity, was found in children than previously reported; this was also higher compared to adults in the same region at a similar time. Contrary to prior reports, we determined children shoulder a significant burden of COVID-19 infection. The role of children's disease transmission must be considered in COVID-19 mitigation strategies including vaccination.


Subject(s)
COVID-19/blood , COVID-19/epidemiology , SARS-CoV-2 , Adolescent , Antibodies, Viral/blood , Antigens, Viral , COVID-19/immunology , COVID-19 Serological Testing , Child , Child, Preschool , Cross-Sectional Studies , Female , Humans , Infant , Infant, Newborn , Male , Multivariate Analysis , Pandemics , Risk Factors , Seroepidemiologic Studies , United States
2.
Cardiol Young ; 31(7): 1202-1204, 2021 Jul.
Article in English | MEDLINE | ID: mdl-33745461

ABSTRACT

SARS-CoV-2, which causes the disease COVID-19, generally has a mild disease course in children. However, a severe post-infectious inflammatory process known as multisystem inflammatory syndrome in children has been observed in association with COVID-19. This inflammatory process is a result of an abnormal immune response with similar clinical features to Kawasaki disease. It is well established that multisystem inflammatory syndrome in children is associated with myocardial dysfunction, coronary artery dilation or aneurysms, and occasionally arrhythmias. The most common electrocardiographic abnormalities seen include premature atrial or ventricular ectopy, variable degrees of atrioventricular block, and QTc prolongation, and rarely, haemodynamically significant arrhythmias necessitating extracorporeal membrane oxygenation support. However, presentation with fever, hypotension, and relative bradycardia with a left axis idioventricular rhythm has not been previously reported. We present a case of a young adolescent with multisystem inflammatory syndrome in children with myocarditis and a profoundly inappropriate sinus node response to shock with complete resolution following intravenous immunoglobulin.


Subject(s)
COVID-19 , Mucocutaneous Lymph Node Syndrome , Adolescent , Child , Humans , Mucocutaneous Lymph Node Syndrome/complications , Mucocutaneous Lymph Node Syndrome/diagnosis , Mucocutaneous Lymph Node Syndrome/drug therapy , SARS-CoV-2 , Sick Sinus Syndrome , Systemic Inflammatory Response Syndrome
4.
Pediatr Infect Dis J ; 28(6): 545-7, 2009 Jun.
Article in English | MEDLINE | ID: mdl-19483524

ABSTRACT

Human parechovirus-3 (HPeV-3) is an emerging pathogen that has been described as a cause of neonatal sepsis. Human parechoviruses are a family of viruses closely related to enteroviruses; however, enteroviral PCR will not detect HPeVs. We present clinical details of neonatal meningoencephalitis and hepatitis-coagulopathy syndrome caused by HPeV-3 infection.


Subject(s)
Meningoencephalitis/diagnosis , Parechovirus/isolation & purification , Picornaviridae Infections/diagnosis , Sepsis/diagnosis , Acyclovir/therapeutic use , Antiviral Agents/therapeutic use , Cerebrospinal Fluid/virology , Humans , Infant, Newborn , Male , Meningoencephalitis/drug therapy , Meningoencephalitis/virology , Parechovirus/genetics , Parechovirus/pathogenicity , Picornaviridae Infections/drug therapy , Picornaviridae Infections/virology , Polymerase Chain Reaction , Sepsis/drug therapy , Sepsis/virology
SELECTION OF CITATIONS
SEARCH DETAIL
...